Stoke Therapeutics, Inc. Common Stock (STOK) Stock
Key stats
- Market cap
- $1.82B
- Price / Earnings ratio
- -7.3x
- EPS (TTM)
- -$3.80
- Volume
- Loading
- 52-week high
- $40.22
- 52-week low
- $21.81
Source: third-party data provider, as of November 13, 2026
Compare with STOK
Recent news

Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
STOK

Stoke Therapeutics Q3 Earnings Call Highlights
Stoke Therapeutics Q3 Earnings Call Highlights
STOK

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
STOK

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
STOK
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 58.10
- MACD 12/26/9
- 0.33
- EMA 9 of MACD
- 0.06
- MACD histogram
- 0.27
- SMA 50
- $26.60
- Price above SMA 50
- EMA 50
- $26.98
- Price above EMA 50
- SMA 200
- $30.83
- Price below SMA 200
- EMA 200
- $29.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
STOK

Stoke Therapeutics Q3 Earnings Call Highlights
Stoke Therapeutics Q3 Earnings Call Highlights
STOK

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
STOK

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
STOK

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
STOK

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
STOK

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
STOK

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
STOK

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
STOK

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
STOK
News tone: automated (AI) classification of the article's content, not a price prediction.
About Stoke Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ian F. Smith A.C.A., C.P.A. | CEO & Director | 1966 |
| Mr. Thomas Edward Leggett | Chief Financial Officer | 1977 |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder & Independent Director | 1959 |
| Mr. Jason Hoitt | Chief Patient Officer | 1978 |
| Ms. Isabel Aznarez Ph.D. | Co-Founder & CTO | 1972 |
| Dr. Thomas McCauley Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Jonathan Allan J.D. | Corporate Secretary, Compliance Officer & General Counsel | 1990 |
| Susan Willson | Vice President of Corporate Communications | — |
| Ms. Sara Den Besten | Chief People Officer | — |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer | 1960 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 58.10
- MACD 12/26/9
- 0.33
- EMA 9 of MACD
- 0.06
- MACD histogram
- 0.27
- SMA 50
- $26.60
- Price above SMA 50
- EMA 50
- $26.98
- Price above EMA 50
- SMA 200
- $30.83
- Price below SMA 200
- EMA 200
- $29.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $40.00
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.9 | +5.1 | ||||||||||
| 2022 | -17.6 | +3.7 | +6.5 | -33.8 | -19.2 | +9.8 | +7.4 | +4.4 | -15.5 | +16.6 | -44.1 | +25.9 |
| 2023 | +9.6 | -4.0 | -4.7 | +8.2 | +13.5 | -5.8 | -37.7 | -11.9 | -28.9 | +3.3 | -7.1 | +33.2 |
| 2024 | -17.4 | +58.3 | +76.9 | -18.2 | +26.5 | -12.7 | +7.9 | -1.2 | -18.2 | -0.1 | -5.8 | -8.6 |
| 2025 | +1.9 | -31.9 | -10.1 | +56.7 | -3.3 | +14.5 | +10.3 | +53.1 | +20.0 | +27.3 | +18.4 | +5.5 |
| 2026 | -1.8 | +18.3 | -11.3 | +2.3 | -6.6 | +7.4 | -11.8 | +5.5 | -15.8 | +1.1 | +4.8 |



